TB-500: thymosin β4 dose-response findings

Study doses and neurological outcomes

In the 2014 embolic-stroke study in male Wistar rats, full-length thymosin β4 improved neurological function at 2 and 12 mg/kg, with significant differences from day 14 through day 56. The 18 mg/kg arm showed no significant benefit. These were intraperitoneal study doses in rats, with treatment beginning after the experimental stroke.

That uncooperative high-dose arm seems especially worth my time. It leaves room for a real effect at the lower tested amounts while refusing a tidy rising line. The authors' dose-response result describes this experiment; it cannot establish an effective amount for a person or for a different molecule. A lack of significant benefit at 18 mg/kg also leaves the reason for the outcome unresolved.

Full-length thymosin β4 and its fragment

TB-500 is the synthetic Ac-LKKTETQ fragment corresponding to residues 17–23 of the 43-amino-acid thymosin β4 protein. The seven-residue fragment carries an actin-binding motif. Most of the encouraging efficacy literature concerns the full-length parent protein.

The structural study of thymosin β4 bound to actin explains how the parent holds individual actin units in reserve, capping both ends of a monomer. Actin forms part of the internal framework cells rearrange as they move. The review of thymosin β4 mechanisms connects this binding to migration, angiogenesis and reduced scar-forming cells across experimental models.

I regard those experiments as a good reason to investigate the protein. Applying its entire portfolio of actions to the short fragment requires separate evidence. Even a shared stretch of sequence leaves much of the molecule different. The fragment has no completed controlled human trial establishing an effective treatment.

Human observations

A randomised intravenous Phase 1 study in 40 healthy volunteers tested full-length synthetic thymosin β4. It was well tolerated, with infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events. The investigators examined safety and pharmacokinetics, the way a substance moves through and leaves the body.

I value that tolerability information within its actual boundaries: healthy volunteers, the parent protein, early observation. It cannot answer whether TB-500 restores a torn muscle or whether repeated exposure to the fragment is safe. The 2026 review of musculoskeletal peptide therapies describes how animal-model promise coexists with scarce rigorous human safety data.

Recovery anecdotes and cancer cautions

People in research-use communities describe easier joint movement, less soreness and apparently faster soft-tissue recovery. Other accounts mention local redness or swelling, tiredness, headache, light-headedness, flu-like feelings and occasional nausea. These are anecdotal reports, without the controls or verified material needed for clinical evidence. I hear the disappointing accounts as clearly as the enthusiastic ones; neither kind can settle an efficacy question.

Cell movement and new-vessel growth also create a theoretical concern around cancer. The parent protein's pro-migratory and pro-angiogenic biology gives that question a mechanistic basis; a clinical tumour risk from the fragment remains unmeasured. Effects around clotting disorders or surgery are precautionary questions based on mechanism, with no human fragment studies to settle them. Pregnancy, breastfeeding and development likewise lack safety data.

TB-500 has no approved therapeutic indication and is prohibited in sport. Research-grade identity, purity and sequence are additional uncertainties. My reservation about its halo begins with the dose-response result, then grows sharper at the point where the parent protein's evidence is handed to the fragment.